Wall Street analyst estimates for Boundless Bio, Inc. (BOLD): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 13 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 20 |
| Avg rating (1-5) | 0.25 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.56 | ||
| 2026-08-04 | $-1.06 | $-1.06 | +0.0% |
| 2026-05-08 | $-0.60 | $-0.51 | -17.6% |
| 2026-03-09 | $-0.58 | $-0.44 | -31.8% |
| 2025-11-05 | $-0.62 | $-0.53 | -17.0% |
| 2025-08-05 | $-0.70 | $-0.75 | +6.7% |
| 2025-05-09 | $-0.71 | $-0.68 | -4.4% |
| 2025-03-27 | $-0.74 | $-0.74 | +0.0% |
Valuation Ratios
| Price / Book | 0.96 |
| EV / EBITDA | -0.76 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | $1.1M | $1.3M |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | -$1.1M | -$1.3M |
| Research & Development | $48.8M | $75.9M | $104.4M | $19.3M | $37.2M | $42.6M | $55.3M | $44.8M |
| Selling, General & Admin | $11.3M | $17.3M | $30.0M | $6.0M | $9.3M | $12.2M | $18.0M | $18.7M |
| Operating Expenses | $60.0M | $93.2M | $134.4M | $25.3M | $46.5M | $54.8M | $72.2M | $62.3M |
| Operating Income | -$60.0M | -$93.2M | -$134.4M | -$25.3M | -$46.5M | -$54.8M | -$73.3M | -$63.6M |
| EBITDA | -$58.1M | -$88.7M | -$121.4M | -$24.5M | -$45.0M | -$48.5M | -$64.3M | -$56.9M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$59.7M | -$92.5M | -$128.8M | -$25.2M | -$45.9M | -$49.4M | -$65.4M | -$58.2M |
| Income Tax | $378000 | -$2.2M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$59.7M | -$90.2M | -$128.8M | -$25.2M | -$45.9M | -$49.4M | -$65.4M | -$58.2M |
| EPS | $-5.59 | $-3.40 | $-2.93 | $-1.13 | $-2.06 | $-2.22 | $-3.85 | $-2.60 |
| EPS (Diluted) | $-5.59 | $-3.40 | $-2.93 | $-1.13 | $-2.06 | $-2.22 | $-3.85 | $-2.60 |
| Shares Outstanding (Diluted) | $10.7M | $26.6M | $44.0M | $22.2M | $22.2M | $22.2M | $17.0M | $22.4M |
Price
| Price | $2.82 |
| Market Cap | $63M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANTX · INTS · ITRM · NXTC · PLUR · PSTV · QTTB
Explore sector: Healthcare · Biotechnology
More sections of BOLD: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks